CDKN2A and neoplasm: Of note and across BCBrM subtypes, results illustrated gains in chromosomes associated with known driver genes, such as in 8q (MYC), 17q12 (ERBB2, GRB7), and 20q13 (AURKA) as well as losses in regions known to contain tumor suppressive genes (e.g. 9p21/CDKN2A, 13q14/RB1, 17p13/TP53, 17q21/BRCA1) that have previously been shown to be altered in metastatic BC and BCBrM [5, 26, 57].